Skip to main content

Royalty Pharma plc

For the period ended Dec 31, 2025. Filed Feb 11, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

RPRX$68.77+2.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

ROYALTY PHARMA PLC
(Registrant)
Date: February 11, 2026/s/ Pablo Legorreta
Pablo Legorreta
Chief Executive Officer
Date: February 11, 2026/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Terrance Coyne and Arthur McGivern, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Pablo LegorretaChairman of the Board, Director & Chief Executive Officer (Principal Executive Officer and Royalty Pharma plc’s authorized representative in the United States)February 11, 2026
Pablo Legorreta
/s/ Terrance CoyneExecutive Vice President & Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)February 11, 2026
Terrance Coyne
/s/ Bonnie BasslerDirectorFebruary 11, 2026
Bonnie Bassler
/s/ Vlad CoricDirectorFebruary 11, 2026
Vlad Coric
/s/ Errol De SouzaDirectorFebruary 11, 2026
Errol De Souza
/s/ Catherine EngelbertDirectorFebruary 11, 2026
Catherine Engelbert
/s/ Carole HoDirectorFebruary 11, 2026
Carole Ho
/s/ David HodgsonDirectorFebruary 11, 2026
David Hodgson
/s/ Ted LoveDirectorFebruary 11, 2026
Ted Love
/s/ Gregory NordenDirectorFebruary 11, 2026
Gregory Norden
/s/ Elizabeth WeathermanDirectorFebruary 11, 2026
Elizabeth Weatherman
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.